• Top product Humira will remain a category leader, at least until its 2016 patent expiration; Limited exposure to patent expirations over the next two years; Modest leverage; Good cash flow generation; and Conservative financial policies. High dependence on a single product; and Near-term pipeline is a little light in high-potential prospects. The ratings on North Chicago, Ill.-based AbbVie Inc. reflect its "strong" business risk profile and "modest" financial risk profile. In the business risk profile, Standard&Poor's Ratings Services incorporates the expectation that AbbVie's key product--arthritis treatment Humira--will keep growing through additional uses and by expanding its pool of patients. AbbVie benefits from a drug pipeline that, although modest for a company of its size, could provide topline
